blue cross blue shield and glp 1 plans reverse course on GLP-1 coverage Why we are changing coverage

Berdous D, Berney X, Sanchez-Archidona AR, Jan M, Roujeau C, Lopez-Mejia IC, et al

Hypoglycaemic therapy in frail older people with type 2 diabetes mellitusa choice determined by metabolic phenotype

Zinc is your skin's healing hero

While scientists dont know exactly how caffeine works in the brain, the running theory is that it binds to adenosine receptors, preventing a typically adenosine-induced slowdown of wake-promoting brain regions

At the time we first started pursuing this litigation, Mounjaro was probably the only label that listed something related to gastroparesis, but it is in no way adequate

Overall, IV NAD+ therapy is a powerful tool in the longevity toolbox when used judiciously